• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解开谜题:SARS-CoV-2 蛋白组中非定义性突变可能影响疫苗效力。

Unlocking the puzzle: non-defining mutations in SARS-CoV-2 proteome may affect vaccine effectiveness.

机构信息

Center for Biological Research Margarita Salas, Spanish National Research Council (CSIC), Madrid, Spain.

National Center for Biotechnology, Spanish National Research Council (CSIC), Madrid, Spain.

出版信息

Front Public Health. 2024 Aug 15;12:1386596. doi: 10.3389/fpubh.2024.1386596. eCollection 2024.

DOI:10.3389/fpubh.2024.1386596
PMID:39228849
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11369981/
Abstract

INTRODUCTION

SARS-CoV-2 variants are defined by specific genome-wide mutations compared to the Wuhan genome. However, non-clade-defining mutations may also impact protein structure and function, potentially leading to reduced vaccine effectiveness. Our objective is to identify mutations across the entire viral genome rather than focus on individual mutations that may be associated with vaccine failure and to examine the physicochemical properties of the resulting amino acid changes.

MATERIALS AND METHODS

Whole-genome consensus sequences of SARS-CoV-2 from COVID-19 patients were retrieved from the GISAID database. Analysis focused on Dataset_1 (7,154 genomes from Italy) and Dataset_2 (8,819 sequences from Spain). Bioinformatic tools identified amino acid changes resulting from codon mutations with frequencies of 10% or higher, and sequences were organized into sets based on identical amino acid combinations.

RESULTS

Non-defining mutations in SARS-CoV-2 genomes belonging to clades 21 L (Omicron), 22B/22E (Omicron), 22F/23A (Omicron) and 21J (Delta) were associated with vaccine failure. Four sets of sequences from Dataset_1 were significantly linked to low vaccine coverage: one from clade 21L with mutations L3201F (ORF1a), A27- (S) and G30- (N); two sets shared by clades 22B and 22E with changes A27- (S), I68- (S), R346T (S) and G30- (N); and one set shared by clades 22F and 23A containing changes A27- (S), F486P (S) and G30- (N). Booster doses showed a slight improvement in protection against Omicron clades. Regarding 21J (Delta) two sets of sequences from Dataset_2 exhibited the combination of non-clade mutations P2046L (ORF1a), P2287S (ORF1a), L829I (ORF1b), T95I (S), Y145H (S), R158- (S) and Q9L (N), that was associated with vaccine failure.

DISCUSSION

Vaccine coverage associations appear to be influenced by the mutations harbored by marketed vaccines. An analysis of the physicochemical properties of amino acid revealed that primarily hydrophobic and polar amino acid substitutions occurred. Our results suggest that non-defining mutations across the proteome of SARS-CoV-2 variants could affect the extent of protection of the COVID-19 vaccine. In addition, alteration of the physicochemical characteristics of viral amino acids could potentially disrupt protein structure or function or both.

摘要

简介

与武汉基因组相比,SARS-CoV-2 变体是通过特定的全基因组突变来定义的。然而,非谱系定义的突变也可能影响蛋白质结构和功能,从而可能导致疫苗效力降低。我们的目标是识别整个病毒基因组中的突变,而不是专注于可能与疫苗失败相关的单个突变,并研究由此产生的氨基酸变化的理化性质。

材料和方法

从 GISAID 数据库中检索了 COVID-19 患者的 SARS-CoV-2 全基因组共识序列。分析集中在数据集 1(来自意大利的 7154 个基因组)和数据集 2(来自西班牙的 8819 个序列)上。生物信息学工具确定了频率为 10%或更高的密码子突变导致的氨基酸变化,并且根据相同的氨基酸组合将序列组织成组。

结果

属于谱系 21L(Omicron)、22B/22E(Omicron)、22F/23A(Omicron)和 21J(Delta)的 SARS-CoV-2 基因组中的非定义突变与疫苗失败有关。数据集 1 中的四个序列集与低疫苗覆盖率显著相关:一个来自谱系 21L,突变为 L3201F(ORF1a)、A27-(S)和 G30-(N);两个来自谱系 22B 和 22E 的序列集共享,变化为 A27-(S)、I68-(S)、R346T(S)和 G30-(N);一个来自谱系 22F 和 23A 的序列集共享,包含 A27-(S)、F486P(S)和 G30-(N)的变化。加强针剂量对 Omicron 谱系的保护作用略有提高。关于 21J(Delta),数据集 2 中的两个序列集表现出非谱系突变 P2046L(ORF1a)、P2287S(ORF1a)、L829I(ORF1b)、T95I(S)、Y145H(S)、R158-(S)和 Q9L(N)的组合,与疫苗失败有关。

讨论

疫苗覆盖率的关联似乎受到市场疫苗所携带突变的影响。对氨基酸理化性质的分析表明,主要发生了疏水性和极性氨基酸取代。我们的结果表明,SARS-CoV-2 变体全蛋白质组中的非定义突变可能会影响 COVID-19 疫苗的保护程度。此外,病毒氨基酸理化特性的改变可能会破坏蛋白质结构或功能,或两者兼而有之。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a422/11369981/b2db6f9a1f14/fpubh-12-1386596-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a422/11369981/9fd9189ec698/fpubh-12-1386596-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a422/11369981/14fcb74d070d/fpubh-12-1386596-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a422/11369981/bb869fcaca25/fpubh-12-1386596-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a422/11369981/b2db6f9a1f14/fpubh-12-1386596-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a422/11369981/9fd9189ec698/fpubh-12-1386596-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a422/11369981/14fcb74d070d/fpubh-12-1386596-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a422/11369981/bb869fcaca25/fpubh-12-1386596-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a422/11369981/b2db6f9a1f14/fpubh-12-1386596-g004.jpg

相似文献

1
Unlocking the puzzle: non-defining mutations in SARS-CoV-2 proteome may affect vaccine effectiveness.解开谜题:SARS-CoV-2 蛋白组中非定义性突变可能影响疫苗效力。
Front Public Health. 2024 Aug 15;12:1386596. doi: 10.3389/fpubh.2024.1386596. eCollection 2024.
2
Molecular evolution of SARS-CoV-2 from December 2019 to August 2022.SARS-CoV-2 的分子进化:2019 年 12 月至 2022 年 8 月。
J Med Virol. 2023 Jan;95(1):e28366. doi: 10.1002/jmv.28366.
3
Genome sequence diversity of SARS-CoV-2 obtained from clinical samples in Uzbekistan.乌兹别克斯坦临床样本中获得的 SARS-CoV-2 的基因组序列多样性。
PLoS One. 2022 Jun 27;17(6):e0270314. doi: 10.1371/journal.pone.0270314. eCollection 2022.
4
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
5
Mutation Analysis of SARS-CoV-2 Variants Isolated from Symptomatic Cases from Andhra Pradesh, India.印度安得拉邦有症状病例中分离的 SARS-CoV-2 变异株的突变分析。
Viruses. 2023 Jul 29;15(8):1656. doi: 10.3390/v15081656.
6
Evolutionary and Phylogenetic Dynamics of SARS-CoV-2 Variants: A Genetic Comparative Study of Taiyuan and Wuhan Cities of China.SARS-CoV-2 变异株的进化与系统发育动态:中国太原市与武汉市的遗传比较研究。
Viruses. 2024 Jun 3;16(6):907. doi: 10.3390/v16060907.
7
Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.人工智能预测 SARS-CoV-2 的免疫原性景观,从而为疫苗设计提供通用蓝图。
Sci Rep. 2020 Dec 23;10(1):22375. doi: 10.1038/s41598-020-78758-5.
8
Evolutionary Tracking of SARS-CoV-2 Genetic Variants Highlights an Intricate Balance of Stabilizing and Destabilizing Mutations.SARS-CoV-2 基因变异的进化追踪突显了稳定和不稳定突变之间的复杂平衡。
mBio. 2021 Aug 31;12(4):e0118821. doi: 10.1128/mBio.01188-21. Epub 2021 Jul 20.
9
Characterisation of SARS-CoV-2 clades based on signature SNPs unveils continuous evolution.基于特征 SNP 对 SARS-CoV-2 进化枝进行特征描述揭示了其持续进化。
Methods. 2022 Jul;203:282-296. doi: 10.1016/j.ymeth.2021.09.005. Epub 2021 Sep 20.
10
Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)基因组中特定变异的有害突变揭示了免疫反应及预防性疫苗开发的潜力。
Front Pharmacol. 2023 Feb 7;14:1090717. doi: 10.3389/fphar.2023.1090717. eCollection 2023.

本文引用的文献

1
Modulation of biophysical properties of nucleocapsid protein in the mutant spectrum of SARS-CoV-2.SARS-CoV-2 突变谱中核衣壳蛋白生物物理特性的调制。
Elife. 2024 Jun 28;13:RP94836. doi: 10.7554/eLife.94836.
2
A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety.新型冠状病毒2变种与疫苗综述:病毒特性、突变、疫苗效力及安全性
Infect Med (Beijing). 2023 Sep 12;2(4):247-261. doi: 10.1016/j.imj.2023.08.005. eCollection 2023 Dec.
3
Some common deleterious mutations are shared in SARS-CoV-2 genomes from deceased COVID-19 patients across continents.
一些常见的有害突变存在于来自不同大洲的 COVID-19 死亡患者的 SARS-CoV-2 基因组中。
Sci Rep. 2023 Oct 30;13(1):18644. doi: 10.1038/s41598-023-45517-1.
4
Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study.2021 年 7 月 12 日至 2022 年 6 月 6 日荷兰针对 SARS-CoV-2 感染的初级和加强 COVID-19 疫苗有效性:一项前瞻性队列研究。
Int J Infect Dis. 2023 Aug;133:36-42. doi: 10.1016/j.ijid.2023.04.401. Epub 2023 Apr 20.
5
Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.2021-2022 年比利时接触者追踪的疫苗对阿尔法、德尔塔和奥密克戎 SARS-COV-2 感染传播的有效性。
Vaccine. 2023 May 11;41(20):3292-3300. doi: 10.1016/j.vaccine.2023.03.069. Epub 2023 Apr 5.
6
The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体受体结合域中的突变集对RBD-ACE2复合物稳定性的影响。
Future Virol. 2023 Mar. doi: 10.2217/fvl-2022-0152. Epub 2023 Apr 6.
7
An update on SARS-CoV-2 immunization and future directions.新型冠状病毒2型免疫接种的最新情况及未来方向。
Front Pharmacol. 2023 Mar 9;14:1125305. doi: 10.3389/fphar.2023.1125305. eCollection 2023.
8
BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design.BNT162b2 对 5-11 岁儿童与 COVID-19 相关的急诊科和紧急护理就诊的影响:一项阴性测试设计。
J Pediatric Infect Dis Soc. 2023 Apr 18;12(3):177-179. doi: 10.1093/jpids/piad005.
9
Development of nucleocapsid-specific monoclonal antibodies for SARS-CoV-2 and their ELISA diagnostics on an automatic microfluidic device.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的核衣壳特异性单克隆抗体的开发及其在自动微流控装置上的酶联免疫吸附测定(ELISA)诊断
Sens Actuators B Chem. 2023 Apr 1;380:133331. doi: 10.1016/j.snb.2023.133331. Epub 2023 Jan 8.
10
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.奥密克戎变异株 BQ.1、BQ.1.1、BA.4.6、BF.7 和 BA.2.75.2 增强型中和抗性。
Cell Host Microbe. 2023 Jan 11;31(1):9-17.e3. doi: 10.1016/j.chom.2022.11.012. Epub 2022 Nov 22.